Tuesday, October 25, 2011
DLVR Therapeutics Inc., of Toronto, completed its seed round investment, bringing the total raised to $2 million in cash and in-kind support. MaRS Innovation joined the University Health Network and the Ontario Institute for Cancer Research (OICR) as investors in the privately held company.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.